Form 8-K - Current report:
SEC Accession No. 0001193125-25-130709
Filing Date
2025-05-29
Accepted
2025-05-29 16:38:45
Documents
29
Period of Report
2025-05-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d948981d8k.htm   iXBRL 8-K 39919
2 EX-1.1 d948981dex11.htm EX-1.1 182287
3 EX-4.1 d948981dex41.htm EX-4.1 79836
4 EX-5.1 d948981dex51.htm EX-5.1 14505
5 EX-99.1 d948981dex991.htm EX-99.1 9482
6 EX-99.2 d948981dex992.htm EX-99.2 50562
7 EX-99.3 d948981dex993.htm EX-99.3 9787
11 GRAPHIC g948981g0528081157645.jpg GRAPHIC 4398
12 GRAPHIC g948981g0528081405368.jpg GRAPHIC 5112
13 GRAPHIC g948981g0529113944158.jpg GRAPHIC 2531
14 GRAPHIC g948981g65a01.jpg GRAPHIC 43580
15 GRAPHIC g948981g65a02.jpg GRAPHIC 142840
16 GRAPHIC g948981g65a03.jpg GRAPHIC 99373
17 GRAPHIC g948981g65a04.jpg GRAPHIC 147335
18 GRAPHIC g948981g65a05.jpg GRAPHIC 57834
19 GRAPHIC g948981g65a06.jpg GRAPHIC 54702
20 GRAPHIC g948981g65a07.jpg GRAPHIC 106442
21 GRAPHIC g948981g65a08.jpg GRAPHIC 115344
  Complete submission text file 0001193125-25-130709.txt   1688455

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA tsha-20250528.xsd EX-101.SCH 2845
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20250528_lab.xml EX-101.LAB 18738
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20250528_pre.xml EX-101.PRE 11704
31 EXTRACTED XBRL INSTANCE DOCUMENT d948981d8k_htm.xml XML 3767
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 251004092
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)